

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Information for the public

Published: 24 July 2019

www.nice.org.uk

Blinatumomab (Blincyto) is available on the NHS as a possible treatment for Philadelphia-chromosome-negative, CD19-positive, B-precursor acute lymphoblastic leukaemia in adults with minimal residual disease of at least 0.1%, only if the disease is in first complete remission.

If you are not eligible for blinatumomab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Cancer Society](#), 0208 374 4821
- [Leukaemia CARE](#), 08088 010 444
- [Bloodwise](#), 0808 2080 888
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3467-6